SCHEMBL20920102

SCHEMBL20920102

O=C(NC(CF)c1ccccc1)c1nc2cc3c(-c4ccncc4)n[nH]c3cc2[nH]1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 19/20 0.49
MAPK3 P27361 7/20 0.46
CDK2 P24941 3/20 0.42
PAK4 O96013 2/20 0.42
MAPK13 O15264 2/20 0.41
ROCK2 O75116 2/20 0.41
RPS6KA5 O75582 2/20 0.41
MAP4K4 O95819 2/20 0.41
PRKCG P05129 2/20 0.41
CDK1 P06493 2/20 0.41
RPS6KB1 P23443 2/20 0.41
AKT1 P31749 2/20 0.41
AKT2 P31751 2/20 0.41
CLK2 P49760 2/20 0.41
GSK3A P49840 2/20 0.41
GSK3B P49841 2/20 0.41
IRAK1 P51617 2/20 0.41
RPS6KA3 P51812 2/20 0.41
NEK4 P51957 2/20 0.41
CDK5 Q00535 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30554370 1.00 MAPK1 (0.49) MAPK1MAPK3CDK2PAK4MAPK13
SCHEMBL20931407 0.92 MAPK1 (0.59) MAPK1MAPK3CDK2PAK4MAPK13
SCHEMBL20916798 0.92 MAPK1 (0.59) MAPK1MAPK3CDK2PAK4MAPK13
SCHEMBL30554283 0.92 MAPK1 (0.59) MAPK1MAPK3CDK2PAK4MAPK13
SCHEMBL20931757 0.91 MAPK1 (0.55) MAPK1MAPK3
SCHEMBL30554335 0.91 MAPK1 (0.55) MAPK1MAPK3
SCHEMBL22284218 0.91 MAPK1 (0.55) MAPK1MAPK3
SCHEMBL30554291 0.90 ROCK1 (0.53) MAPK1MAPK3CDK2PAK4MAPK13
SCHEMBL20916842 0.90 ROCK1 (0.53) MAPK1MAPK3CDK2PAK4MAPK13
SCHEMBL22284205 0.89 MAPK1 (0.48) MAPK1MAPK3CDK2PAK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112020357-B Salt of indazolyl-containing tricyclic derivative and crystal form thereof 上海翰森生物医药科技有限公司 2023-08-29 CN disclosed
CN-110546150-B Pyrazolyl-containing tricyclic derivatives, preparation method and application thereof 江苏豪森药业集团有限公司 2021-12-21 CN disclosed
CN-112020357-A Salts of indazolyl-containing tricyclic derivatives and crystal forms thereof 上海翰森生物医药科技有限公司 2020-12-01 CN disclosed
WO-2020200161-A1 SALT OF INDAZOLYL-CONTAINING TRICYCLIC DERIVATIVE AND CRYSTAL FORM THEREOF 上海翰森生物医药科技有限公司 2020-10-08 WO disclosed
WO-2020200161-A1 SALT OF INDAZOLYL-CONTAINING TRICYCLIC DERIVATIVE AND CRYSTAL FORM THEREOF 上海翰森生物医药科技有限公司 2020-10-08 WO disclosed
EP-3699179-A1 PYRAZOLYL-CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (CN) 2020-08-26 EP disclosed
EP-3699179-A1 PYRAZOLYL-CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (CN) 2020-08-26 EP disclosed
US-20200247815-A1 PYRAZOLYL-CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) 2020-08-06 US disclosed
US-20200247815-A1 PYRAZOLYL-CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) 2020-08-06 US disclosed
CN-110546150-A Pyrazolyl-containing tricyclic derivatives, preparation method and application thereof JIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD 2019-12-06 CN disclosed
WO-2019076336-A1 PYRAZOLYL-CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF 江苏豪森药业集团有限公司 2019-04-25 WO disclosed
WO-2019076336-A1 PYRAZOLYL-CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF 江苏豪森药业集团有限公司 2019-04-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200247815-A1 PYRAZOLYL-CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF MAPK1, MAPK11, MAPK14 MAPK1 1/4885MAPK3 14/4885CDK2 280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.